United Kingdom Plasma Therapy Market

The United Kingdom Plasma therapy market size is forecast to grow from approximately USD 23.7 Billion in 2025 to around USD 57.65 Billion by 2035. According to Decision Advisors, a detailed research report on the plasma therapy market indicates that the Self-sufficiency trend dominates the market, accounting for approximately 45% of the total share in the United Kingdom. CSL Behring leads the market with an estimated 25% United Kingdom market share. The company's annual revenue of approximately USD 15-16 billion is making it one of the most influential forces shaping industry trends and overall market growth.

Market Snapshot

• United Kingdom Plasma Therapy Market size (2025): USD 29.25Billion
• Projected United Kingdom Plasma Therapy Market Size (2035): USD 58.05Billion
• United Kingdom Plasma Therapy Market Compound Annual Growth Rate (CAGR): 7.09%
• Base Year: 2025
• Historical Period: 2021–2024
• Forecast Period: 2026–2035

Market Overview/Introduction

The United Kingdom plasma therapy market refers to the healthcare industry involved in the collection, processing, and distribution of human blood plasma to produce life-saving plasma-derived medicines, which include immunoglobulins, albumin, and clotting factors. Plasma therapy is a medical treatment that uses blood plasma components to treat immune deficiencies, bleeding disorders, and other chronic conditions. The market will expand because more people develop rare and chronic diseases, immunoglobulin therapies become more popular, and healthcare facilities become more available. The future offers new possibilities through three technological advances, which include fractionation technology, recombinant plasma products, and AI-based supply chain optimization. Public understanding of early diagnosis and treatment, combined with existing regulatory frameworks and plasma donation center growth, creates vital pathways for plasma therapies to establish themselves as fundamental components of modern precision and regenerative medicine within the United Kingdom healthcare system.

• The UK government supported the NHS Plasma for Medicines Programme, which expanded domestic collection of plasma to manufacture immunoglobulin and albumin therapies. The initiative reduced dependency on imports and improved self-sufficiency in plasma-derived medicinal products for NHS patients with immune and neurological disorders.

• In 2024–2025, NHSBT expanded plasma collection centres across the UK under government support to increase plasma supply for medicinal manufacturing. The scheme focused on boosting donor participation and ensuring stable supply for immunoglobulin treatments used in chronic and rare diseases.

Notable Insights: -

1. The immunoglobulins (IVIG, SCIG) segment dominated the market in 2025 and holds the largest market share, accounting for approximately 62% during the forecast period.
2. The immunology segment dominated the market in 2025 and holds the largest market share, accounting for approximately 40% during the forecast period.
3. The hospitals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 50% during the forecast period.
4. The compound annual growth rate of the United Kingdom Plasma therapy market is 7.09%.
5. The market is likely to achieve a valuation of USD 58.05Billion by 2035.

What is the role of technology in grooming the market?

Technology plays a crucial role in shaping and accelerating the United Kingdom plasma therapy market by improving efficiency, safety, and scalability across the value chain. Advanced apheresis technologies enable faster and safer plasma collection from donors, increasing overall supply. Modern fractionation techniques and automated bioprocessing systems enhance the yield and purity of plasma-derived products such as immunoglobulins and albumin. Digital tracking systems and AI-driven analytics improve donor management, inventory forecasting, and supply chain optimization, reducing wastage and shortages. Cold chain innovations ensure better storage and transportation of sensitive plasma products. Additionally, automation in manufacturing facilities supports consistent quality and regulatory compliance. Emerging technologies like recombinant protein production and pathogen reduction systems further enhance product safety and reliability. Collectively, these technological advancements are driving operational efficiency, cost optimization, and sustainable growth in the U.S. plasma therapy market while meeting rising patient demand for advanced therapies.

Market Drivers

The United Kingdom plasma therapy market is being driven by several key factors. The increasing number of people who have immunodeficiency disorders, together with chronic diseases, creates a continuous demand for plasma-derived medical products, which physicians use to treat these conditions. The market expansion receives additional support from rising quality requirements and sustainability needs, together with new developments in plasma fractionation technology. The increasing number of sports injuries that occur during athletic activities drives more medical facilities to use plasma therapy for their specialized treatment needs. The market develops new possibilities because researchers explore new medical applications and test new treatments. Medical experts can now identify patients who need plasma therapy through enhanced diagnostic methods.

Restrain

The United Kingdom plasma therapy market faces restraints such as limited plasma donor availability, high production and processing costs, and stringent regulatory requirements. Supply chain vulnerabilities, long fractionation timelines, and dependence on specialized infrastructure also restrict scalability. Additionally, price pressures and reimbursement challenges can limit broader patient access to therapies.

Study on the Supply, Demand, Distribution, and Market Environment of the United Kingdom Plasma Therapy Market

The United Kingdom plasma therapy market operates in a highly structured supply-demand environment, where supply is primarily dependent on voluntary plasma donations collected through an extensive network of donation centers, making the U.S. the largest global source of raw plasma. Demand is driven by rising cases of chronic and rare diseases requiring immunoglobulins, albumin, and coagulation factors, creating a persistent supply–demand gap. Distribution is controlled by vertically integrated companies that manage collection, fractionation, and global supply chains. The market environment is shaped by strict FDA regulations, high capital investment, and strong competition among key players. Raw material in this market is human blood plasma, which undergoes fractionation to extract therapeutic proteins. Limited donor availability, seasonal variations, and increasing global demand for plasma-derived medicines further intensify supply pressures, while technological advancements in fractionation and expanding healthcare access continue to support long-term market growth and stability in the U.S. healthcare system.

Price Analysis and Consumer Behaviour Analysis

The United Kingdom plasma therapy market is characterized by relatively high treatment costs due to complex collection, fractionation, and storage processes, as well as stringent regulatory compliance requirements. Plasma-derived therapies such as immunoglobulins and albumin are premium-priced, often leading to annual treatment costs ranging from several thousand to over $100,000 depending on the condition and dosage frequency. Price variation is also influenced by hospital settings, insurance coverage, and availability of specialty plasma products. From a consumer behavior perspective, demand is largely driven by patients with chronic and rare diseases, including immunodeficiency disorders and hemophilia, who require long-term or lifelong therapy. Patients and healthcare providers show strong preference for trusted, branded therapies with proven clinical efficacy and safety. Additionally, increasing awareness, improved diagnosis rates, and expanding insurance reimbursement coverage are significantly boosting adoption of plasma therapies across the United Kingdom healthcare system.

Market Segmentation

The United Kingdom Plasma Therapy Market share is classified into material type, application, and end user 

• The immunoglobulins (IVIG, SCIG) segment dominated the market in 2025 and holds the largest market share, accounting for approximately 62% during the forecast period.

Based on the product type, the plasma therapy market is divided into immunoglobulins (IVIG, SCIG), albumin, coagulation factors (factor VIII, factor IX), and protease inhibitors. Among these, the immunoglobulins (IVIG, SCIG) segment dominated the market in 2025 and holds the largest market share, accounting for approximately 62% during the forecast period. The immunoglobulins (IVIG, SCIG) segment is driven by its extensive use in treating immunodeficiency, autoimmune, and neurological disorders. High clinical effectiveness, recurring long-term treatment needs, strong physician preference, and increasing disease prevalence contribute to sustained demand.

• The immunology segment dominated the market in 2025 and holds the largest market share, accounting for approximately 40% during the forecast period.

Based on the application, the plasma therapy market is divided into immunology, hematology, neurology, and critical care. Among these, the immunology segment dominated the market in 2025 and holds the largest market share, accounting for approximately 40% during the forecast period. The immunology segment in the U.K. is attributed to the high prevalence of primary and secondary immunodeficiency disorders requiring long-term treatment. Strong reliance on immunoglobulin therapies, increasing diagnosis rates, and rising awareness among healthcare providers drive demand.

• The hospitals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 50% during the forecast period.

Based on the end user, the bioplasma therapy market is divided into hospitals, clinics, research institutes, and ambulatory surgical centers. Among these, the hospitals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 50% during the forecast period. The hospitals segment in the U.K. is driven by the availability of advanced healthcare infrastructure, skilled professionals, and specialized equipment required for plasma therapy administration. Hospitals handle complex cases, ensure patient monitoring, and benefit from strong reimbursement systems.

Recent Development

• In September 2025, KalVista Pharmaceuticals reported its operational update and quarterly financial results, highlighting strong early commercial performance of EKTERLY, the first oral on-demand therapy for hereditary angioedema. The company expanded global approvals, including the UK, and strengthened its plasma-derived therapeutic pipeline while advancing commercialization and patient access initiatives.
• In August 2024, Accord Healthcare continued its strong growth trajectory, highlighting expansion across generics, biosimilars, and specialty medicines. The company strengthened its global plasma therapy capabilities through strategic initiatives, supporting wider access to plasma-derived treatments and enhancing its UK-linked pharmaceutical manufacturing and supply operations for improved patient care and market reach.

Competitive Analysis

The report offers the appropriate analysis of the key organisations/companies involved within the United Kingdom Plasma therapy market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Top Key Companies in the United Kingdom Plasma Therapy Market

• CSL Limited
• Grifols
• Takeda Pharmaceutical Company
• Octapharma
• Kedrion Biopharma
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United Kingdom, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the United Kingdom plasma therapy market based on the below-mentioned segments

United Kingdom Plasma Therapy Market, By Product Type

• Immunoglobulins (IVIG, SCIG)
• Albumin
• Coagulation Factors (Factor VIII, Factor IX)
• Protease Inhibitors

United Kingdom Plasma Therapy Market, By Application

• Immunology
• Hematology
• Neurology
• Critical Care

United Kingdom Plasma Therapy Market, By End User

• Hospitals 
• Clinics
• Research Institutes
• Ambulatory Surgical Centers

Frequently Asked Questions (FAQ)

Q. What factors are improving plasma collection efficiency in the UK?

A. Plasma collection efficiency in the UK has improved due to expanded NHS donor centres, advanced apheresis technology, and digital donor management systems. These innovations have increased donation speed, improved donor safety, and ensured a more stable supply of plasma for fractionation into immunoglobulins and other therapies.

Q. How is the UK reducing dependency on imported plasma medicines?

A. The UK has reduced dependency on imported plasma medicines by investing in domestic fractionation capabilities and expanding NHS Plasma for Medicines programmes. Government-backed initiatives have encouraged local plasma collection, enabling partial self-sufficiency in producing immunoglobulins and albumin for NHS hospitals.

Q. What challenges affect pricing stability in plasma-derived therapies in the UK?

A. Pricing stability is affected by high production costs, limited donor availability, complex fractionation processes, and global supply-demand imbalance. Additionally, dependence on imported raw plasma and strict regulatory requirements increases overall treatment costs, making long-term pricing pressure a key market challenge.

Q. How is patient demand influencing innovation in the UK plasma therapy market?

A. Rising patient demand for long-term treatments in immunology and neurology has driven innovation in recombinant plasma products, improved immunoglobulin formulations, and subcutaneous delivery methods. Companies are focusing on safer, more convenient therapies to improve patient compliance and reduce hospital dependency.